PL3377637T3 - Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry - Google Patents

Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry

Info

Publication number
PL3377637T3
PL3377637T3 PL16826873T PL16826873T PL3377637T3 PL 3377637 T3 PL3377637 T3 PL 3377637T3 PL 16826873 T PL16826873 T PL 16826873T PL 16826873 T PL16826873 T PL 16826873T PL 3377637 T3 PL3377637 T3 PL 3377637T3
Authority
PL
Poland
Prior art keywords
wounds
disorders
diseases
skin
compositions
Prior art date
Application number
PL16826873T
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3377637(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech, Inc. filed Critical Krystal Biotech, Inc.
Publication of PL3377637T3 publication Critical patent/PL3377637T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL16826873T 2016-04-08 2016-12-28 Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry PL3377637T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08
PCT/US2016/068974 WO2017176336A1 (en) 2016-04-08 2016-12-28 Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
EP16826873.8A EP3377637B1 (en) 2016-04-08 2016-12-28 Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin

Publications (1)

Publication Number Publication Date
PL3377637T3 true PL3377637T3 (pl) 2020-09-07

Family

ID=57822104

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16826873T PL3377637T3 (pl) 2016-04-08 2016-12-28 Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry

Country Status (22)

Country Link
US (7) US9877990B2 (pl)
EP (2) EP3377637B1 (pl)
JP (4) JP6970086B2 (pl)
KR (2) KR102985297B1 (pl)
CN (3) CN109072255A (pl)
AU (6) AU2016401692B2 (pl)
CA (1) CA3017487A1 (pl)
CL (3) CL2018002814A1 (pl)
CY (1) CY1123024T1 (pl)
DK (1) DK3377637T3 (pl)
ES (1) ES2796488T3 (pl)
HR (1) HRP20200853T1 (pl)
HU (1) HUE049237T2 (pl)
LT (1) LT3377637T (pl)
MX (2) MX394867B (pl)
PL (1) PL3377637T3 (pl)
PT (1) PT3377637T (pl)
RS (1) RS60410B1 (pl)
SG (1) SG11201808314QA (pl)
SI (1) SI3377637T1 (pl)
SM (1) SMT202000305T1 (pl)
WO (1) WO2017176336A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
ES2796488T3 (es) 2016-04-08 2020-11-27 Krystal Biotech Inc Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel
WO2018089893A1 (en) * 2016-11-14 2018-05-17 The Regents Of The University Of Michigan Compositions and methods for blocking ultraviolet radiation
CA3049652A1 (en) * 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
MX2020011257A (es) * 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
WO2020006486A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
EP3856914A1 (en) * 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
AU2020209687A1 (en) * 2019-01-18 2021-07-29 Osaka University Composition for use in treating dystrophic epidermolysis bullosa
CN113454105A (zh) * 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
AU2020248453A1 (en) * 2019-03-27 2021-10-28 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
US20230118087A1 (en) 2019-09-03 2023-04-20 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
WO2022047229A1 (en) 2020-08-27 2022-03-03 Emory University Novel forms of antiviral nucleosides
IL307350A (en) 2021-04-02 2023-11-01 Krystal Biotech Inc Viral vectors for cancer treatment
US20240424065A1 (en) 2021-10-12 2024-12-26 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法
EP4695408A1 (en) 2023-04-13 2026-02-18 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye
WO2025193129A1 (ru) * 2024-03-15 2025-09-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Средство для лечения буллезных генодерматозов
WO2026094007A1 (en) 2024-11-01 2026-05-07 Krystal Biotech, Inc. Compositions and methods for the treatment of atpase disorders or diseases of the skin
CN119751645B (zh) * 2024-12-31 2026-02-13 北京华熙荣熙生物技术研究有限公司 一种重组ⅶ型胶原蛋白及其制备方法和应用
CN119685407A (zh) * 2025-02-25 2025-03-25 北京唯源立康生物科技股份有限公司 工程化单纯疱疹病毒载体及其用途
CN120248038B (zh) * 2025-04-10 2026-06-09 西安巨子生物基因技术股份有限公司 一种具有紧致抗皱功效的重组vii型胶原蛋白

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
AU737727B2 (en) * 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
EP1083951A4 (en) * 1998-06-12 2004-07-07 Aradigm Corp METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY
JP2003535565A (ja) 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
WO2001064747A1 (en) * 2000-03-02 2001-09-07 Isis Innovation Limited Mutations in spink5 responsible for netherton's syndrome and atopic diseases
EP1356071B1 (en) * 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
EP1381280B1 (en) * 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006050211A2 (en) * 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
EP1827480B1 (en) * 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
EP1838353A2 (en) * 2005-01-21 2007-10-03 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
DK2002003T3 (en) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
EP2963118B1 (en) * 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
WO2008143875A1 (en) * 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
EP2766480B1 (en) * 2011-10-11 2018-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) * 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
WO2014134412A1 (en) * 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
KR102311614B1 (ko) * 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
JP6726824B2 (ja) 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
KR102415811B1 (ko) * 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
MX387839B (es) * 2014-10-31 2025-03-04 Senju Pharma Co Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
US11241505B2 (en) * 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3302575A4 (en) * 2015-05-28 2019-01-16 Coda Biotherapeutics GEMONEDITIERUNGSVEKTOREN
CN109069668B (zh) * 2015-12-14 2023-04-18 宾夕法尼亚州大学信托人 用于眼病的基因疗法
AU2017212713B2 (en) * 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
WO2017165806A1 (en) * 2016-03-25 2017-09-28 Periphagen, Inc. Hsv vectors for delivery of nt3 and treatment of cipn
DK3432912T5 (da) * 2016-03-25 2024-09-16 Periphagen Inc Hsv-vektorer med høj transduktion
ES2796488T3 (es) 2016-04-08 2020-11-27 Krystal Biotech Inc Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
MX2020011257A (es) 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
WO2020006486A1 (en) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
JP2023118838A (ja) 2023-08-25
US10155016B2 (en) 2018-12-18
PT3377637T (pt) 2020-06-17
SMT202000305T1 (it) 2020-07-08
JP2022023174A (ja) 2022-02-07
CA3017487A1 (en) 2017-10-12
RS60410B1 (sr) 2020-07-31
CN122516390A (zh) 2026-08-07
NZ778381A (en) 2025-07-25
CY1123024T1 (el) 2021-10-29
AU2016401692A1 (en) 2018-09-27
EP3377637A1 (en) 2018-09-26
MX2018012135A (es) 2019-03-28
HRP20200853T1 (hr) 2020-08-21
US9877990B2 (en) 2018-01-30
AU2019280069A1 (en) 2020-01-16
KR102985297B1 (ko) 2026-07-06
SG11201808314QA (en) 2018-10-30
KR20250133993A (ko) 2025-09-09
AU2025200334A1 (en) 2025-02-20
US20180169160A1 (en) 2018-06-21
MX2022006072A (es) 2022-06-14
AU2025204575A1 (en) 2025-07-10
JP7815178B2 (ja) 2026-02-17
US11185564B2 (en) 2021-11-30
EP3712273A1 (en) 2020-09-23
AU2022204729A1 (en) 2022-07-21
JP6970086B2 (ja) 2021-11-24
AU2026204351A1 (en) 2026-06-25
US20170290866A1 (en) 2017-10-12
AU2025200334B2 (en) 2025-04-17
US20230149486A1 (en) 2023-05-18
CN122182819A (zh) 2026-06-12
US20230414686A1 (en) 2023-12-28
KR20180128016A (ko) 2018-11-30
JP7480105B2 (ja) 2024-05-09
CL2021000881A1 (es) 2021-09-10
US20220273737A1 (en) 2022-09-01
JP2025185268A (ja) 2025-12-19
ES2796488T3 (es) 2020-11-27
WO2017176336A1 (en) 2017-10-12
JP2019513689A (ja) 2019-05-30
US20190160122A1 (en) 2019-05-30
CL2018002814A1 (es) 2019-02-15
LT3377637T (lt) 2020-07-10
AU2016401692B2 (en) 2019-10-03
MX394867B (es) 2025-03-24
US20200101123A1 (en) 2020-04-02
SI3377637T1 (sl) 2020-08-31
AU2022204729B2 (en) 2025-02-06
HUE049237T2 (hu) 2020-09-28
US12582684B2 (en) 2026-03-24
EP3377637B1 (en) 2020-03-18
US10441614B2 (en) 2019-10-15
DK3377637T3 (da) 2020-05-18
AU2019280069B2 (en) 2022-04-07
CN109072255A (zh) 2018-12-21
CL2023000743A1 (es) 2023-09-29
NZ746213A (en) 2021-08-27
AU2025204575B2 (en) 2026-03-26
US11865148B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
LT3377637T (lt) Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
HUE059752T2 (hu) A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
EP3344632A4 (en) Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
SMT202300260T1 (it) Composti a base di indolinoni e loro utilizzo nel trattamento di patologie fibrotiche
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
PT3307277T (pt) Oligonucleótidos de cadeia simples para utilização no tratamento médico de distúrbios da pele
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
IL246855A0 (en) Materials for use in the treatment of retinitis
SG11201701939UA (en) Cosmetic and/or pharmaceutical composition in the form of a dispersion, method for preparing same and use thereof for skin treatment
SMT202100070T1 (it) Complesso e composizioni per il trattamento di affezioni oculari e cutanee
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
HK1260224A1 (en) Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
AU2016900442A0 (en) PAK1-blocking esters, preparation, and their use in treatment of cancer and other PAK1-dependent diseases/disorders
HK40007519A (en) Vaccines for use in treating various diseases and disorders
HK40027056A (en) Grape skin for use in the treatment of dysbiosis
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases